+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Bioinformatics Partnering Terms and Agreements 2015 to 2022

  • PDF Icon

    Report

  • 750 Pages
  • June 2022
  • Region: Global
  • CurrentPartnering
  • ID: 2987374
The Global Bioinformatics Partnering Terms and Agreements 2015 to 2022 report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.
  • Trends in bioinformatics partnering deals
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active deal makers
  • Financial deal terms for bioinformatics

The Global Bioinformatics Partnering Terms and Agreements 2015 to 2022 report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest bioinformatics agreements announced in the healthcare sectors.

Bioinformatics is the application of computer science and information technology to the field of biology and medicine. Bioinformatics deals with algorithms, databases, information systems, web technologies, artificial intelligence, information and computation theory, software engineering, data mining, image processing, modeling, simulation, signal processing, discrete mathematics, control systems, and statistics, for generating new knowledge of biology and medicine.

Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing power has been embraced in order to speed up the discovery, evaluation and clinical assessment processes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all bioinformatics partnering deals announced since January 2015, including financial terms where available, including over 1600 links to online deal records of actual bioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading bioinformatics deals since 2015. Deals are listed by headline value, signed by big pharma, most active bioinformatics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in bioinformatics dealmaking with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2015, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since Janunary 2015. The chapter is organized by specific bioinformatics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z, deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2015.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products.

Global Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of bioinformatics deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 1500 bioinformatics deals entered into by the world’s biopharma companies
  • Detailed access to actual bioinformatics contracts enter into by the leading bigpharma companies
  • Insight into the terms included in a bioinformatics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in bioinformatics dealmaking
2.1. Introduction
2.2. Bioinformatics partnering over the years
2.3. Most active bioinformatics dealmakers
2.4. Bioinformatics partnering by deal type
2.5. Bioinformatics partnering by therapy area
2.6. Deal terms for bioinformatics partnering
2.6.1 Bioinformatics partnering headline values
2.6.2 Bioinformatics deal upfront payments
2.6.3 Bioinformatics deal milestone payments
2.6.4 Bioinformatics royalty rates
Chapter 3 - Leading bioinformatics deals
3.1. Introduction
3.2. Top bioinformatics deals by value
Chapter 4 - Most active bioinformatics dealmakers
4.1. Introduction
4.2. Most active bioinformatics dealmakers
4.3. Most active bioinformatics partnering company profiles
Chapter 5 - Bioinformatics contracts dealmaking directory
5.1. Introduction
5.2. Bioinformatics contracts dealmaking directory
Chapter 6 - Bioinformatics dealmaking by technology type
Appendices
Appendix 1 - Bioinformatics deals by company A-Z
Appendix 2 - Bioinformatics deals by stage of development
Appendix 3 - Bioinformatics deals by deal type
Appendix 4 - Bioinformatics deals by therapy area
Appendix 5 - Deal type definitions
Appendix 6 - Further reading
Table of figures
Figure 1: Bioinformatics partnering since 2015
Figure 2: Active bioinformatics dealmaking activity
Figure 3: Bioinformatics partnering by deal type since 2015
Figure 4: Bioinformatics partnering by disease type since 2015
Figure 5: Bioinformatics deals with a headline value
Figure 6: Bioinformatics deals with an upfront value
Figure 7: Bioinformatics deals with a milestone value
Figure 8: Bioinformatics deals with a royalty rate value
Figure 9: Top bioinformatics deals by value since 2015
Figure 10: Most active bioinformatics dealmakers sinc 2015

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 1QBit
  • 2bPrecise
  • 3B Medical
  • 3D Signatures
  • 3D Systems
  • 3M
  • 4HF Biotec
  • 10X Genomics
  • 23andMe
  • 111
  • 121nexus
  • A2A Pharmaceuticals
  • A3 Informatics
  • Abarca
  • Abbott Laboratories
  • Abbvie
  • Abramson Cancer Center
  • Abyde
  • Academic Medical Center
  • Accelerated Enrollment Solutions
  • Accelq
  • Accenture
  • AccessDx Laboratory
  • Accuray
  • AccuWeather
  • Acentrus Specialty
  • Achilles Therapeutics
  • Actigraph
  • Active Motif
  • ActX
  • Acuant
  • Acumen Analytics
  • Acurian
  • Adapt Analytics
  • Adaptiiv
  • Adaptive Biotechnologies
  • Adaptive Research
  • ADAS 3D Medical
  • Adents
  • Adhera Therapeutics
  • AdhereHealth
  • Aditx Therapeutics
  • Adracare
  • Advaita
  • Advanced Biological Laboratories
  • Advanced Clinical
  • Advanced Guidance Technologies
  • Advanced Radiation Therapy
  • Advantech
  • Advarra
  • Advocate Health Care
  • Aether
  • Aetion
  • Aetna
  • Aetos Pharma
  • Aevolve
  • Agadia Systems
  • AgaMatrix
  • AgileBio
  • Agilent Technologies
  • AG Mednet
  • AiCure
  • Aidoc
  • Aiforia Technologies
  • AirXpanders
  • AIT Laboratories
  • Akerna
  • Akili Interactive Labs
  • Alector
  • Alexion Pharmaceuticals
  • Alex Therapeutics
  • Alibaba Health
  • Alienware
  • Alira Health
  • Alit Life Science
  • Alkahest
  • Allelica
  • Allergan
  • Alliance for Clinical Research Excellence and Safety (ACRES)
  • Alliance For Clinical Trials In Oncology
  • Allosteric Bioscience
  • Allotrope Foundation
  • Allscripts
  • AllyAlign Health
  • Almac Group
  • Almirall
  • ALS Association
  • AltMed Florida
  • Altoida
  • Alto Neuroscience
  • Alvarado Hospital Medical Center
  • Alyvant
  • Alzheimer's Drug Discovery Foundation
  • Amazon Web Services
  • Amber Pharmacy
  • American Academy of Neurology
  • American Cancer Society
  • American College of Cardiology
  • American Diabetes Association
  • American Heart Association
  • American Medical Association
  • American National Multiple Sclerosis Society
  • American Sleep Apnea Association
  • American Society of Hematology
  • American Speech-Language-Hearing Association
  • American Type Culture Collection (ATCC)
  • American Well
  • Amerinet
  • Amgen
  • Amici Pharmaceuticals
  • Amplifire
  • AMRA
  • Amylyx Pharmaceuticals
  • Amyris
  • Analytical BioSciences
  • Ancestry
  • AnchorDx
  • Andelyn Biosciences
  • Andor Technology
  • Andrew Alliance
  • Anelto
  • Anju Software
  • Annum Health
  • ANP Technologies
  • Antengene
  • Anthem
  • AnthroTronix
  • AO Foundation
  • Apollo Health
  • Apollo Healthcare
  • AppBus
  • Appian Labs
  • Appistry
  • Apple
  • Applied BioMath
  • Applied DNA Sciences
  • AppliedVR
  • Appriss Health
  • Apricity Health
  • Aprima Medical Software
  • Aptar Pharma
  • Arbor Biotechnologies
  • ARCA Biopharma
  • Arc Bio
  • ArcherDX
  • Ares Genetics
  • Argent Development Group
  • Ariana Pharma
  • Aris Global
  • ArisGlobal
  • Arivis
  • Arm
  • Armor
  • Arria
  • Artificial
  • Ascenion
  • Ascensia Diabetes Care
  • ASH Research Collaborative
  • Asimily
  • Aspen Imaging Healthcare
  • Astellas Pharma
  • AstraZeneca
  • Athenahealth
  • ATMPS
  • Atomwise
  • ATUM
  • Audaire Health
  • Aural Analytics
  • Auria Biobank
  • Aurochs
  • Autism Learning Partners
  • Autolomous
  • Automation Anywhere
  • Auxita
  • Avalere Health
  • Avera Health

Methodology

  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

 

 

Loading
LOADING...